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Recent discoveries in itch neurophysiology include itch-
selective neuronal pathways, the clinically relevant non-
histaminergic pathway, and elucidation of the notable 
similarities and differences between itch and pain. Po-
tential involvement of glial cells in itch processing and 
the possibility of glial modulation of chronic itch have 
recently been identified, similarly to the established glial 
modulation of pain processing. This review outlines the 
similarities and differences between itch and pain, and 
how different types of central and peripheral glial cells 
may be differentially involved in the development of ch-
ronic itch akin to their more investigated role in chronic 
pain. Improvements are needed in the management of 
chronic itch, and future basic and interventional studies 
on glial activity modulation would both enhance our 
understanding of mechanisms underlying the chroni-
fication of itch and provide novel opportunities for the 
prevention or treatment of this debilitating and common 
condition. Key words: itch; glia; glial cells; astrocytes; 
micro glia; neurophysiology; satellite glial cells; Schwann 
cells; pain; surrogate models of itch.
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Itch is a sensory modality defined as the “unpleasant 
somatosensation that evokes a desire to scratch” (1). 
In its acute form, itch carries a protective purpose by 
prompting a scratch response in the affected area. In cases 
of pathologically associated itch, e.g. in conditions such 
as psoriasis, prurigo nodularis, uraemic pruritus, drug-
induced pruritus, or atopic dermatitis (AD), however, 
itch often turns into a chronic or frequently recurring 
debilitation. Chronic itch affects millions of individu-
als (2), imposes a significant burden on the quality of 
life of the afflicted patients, and interferes with vital 
functions such as sleep, attention, and sexual activity 
(3, 4). Similar to the events leading to chronification of 
pain conditions, certain pathological predispositions, 
such as inflammatory skin disorders, frequently lead to 
the intensification and chronification of pruritus. This, in 
turn, leads to excessive, recurrent scratching, typically 
worsening the skin lesions and leading to more or pro-
longed pruritus (5, 6). This phenomenon, known as the 
itch–scratch–itch vicious cycle, is physiologically com-
plex and is likely to involve: local inflammatory medi-
ators and structural changes, reward components, and 
the autonomic nervous system (5, 7). In most conditions 
associated with chronic itch, very limited or ambiguous 
evidence is found for the effectiveness of pharmaceutical 
interventions, and the evidence is often characterized by 
off-label small-scale trials or case series. Histamine is 
now widely accepted not to have a key role in evoking 
itch in most of the clinical conditions characterized by 
chronic pruritus (for an overview of itch neurobiology 
and mechanisms, see recent reviews in the field [8, 9]). 
This is in agreement with the fact that these conditions 
are often largely or entirely resistant to treatment with 
topical as well as systemic antihistamines (3, 10). Hence, 
the current treatment regimens for reliev ing itch, beyond 
targeting the underlying disorder, are suboptimal (3). 
Preclinical studies have recently shown that glial cells 
may also play an important role in the development of 
pathological chronic itch (11–13). This review aims to 
recapitulate on these novel findings and highlights the 
similarities and differences between pain and itch in 
relation to neuron-glial interactions. Finally, this paper 
provides an overview of the currently elucidated mole-
cular mechanisms of glial involvement in itch, and future 
interventional opportunities are discussed, in order to 
stimulate further investigation within this novel area. 
ITCH AND PAIN
Itch and pain, although distinct, are highly entwined 
sensory modalities with numerous similarities, but also 
distinct differences. In chronic conditions, both itch and 
pain tend to generalize anatomically, decrease quality 
of life, and precipitate secondary reactive depression 
(14). Notably, mild cutaneous pain is commonly found 
to co-exist with chronic itch, for instance in patients 
with AD and psoriasis, who nonetheless typically 
report itch as their primary sensory complaint (15). 
Itch and pain are also pathophysiologically grouped 
in a similar way; often presenting as inflammatory or 
neuropathic (16). Moreover, itch causes the central 
sensitization-associated signs termed “alloknesis” and 
“hyperknesis”, similar to those produced by painful 
stimuli, “allodynia” and “hyperalgesia”, respectively 
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(14). Alloknesis describes the dysesthetic state, in 
which otherwise non-pruritic stimuli, e.g. light touch, 
provoke a sensation of itch (17, 18), and hyperknesis is 
an exaggerated itch response elicited after a normally 
pruritic or prickling stimulus (16, 19). A study by van 
Laarhoven et al. (20) compared somatosensory proces-
sing of itch and pain using quantitative sensory testing 
(QST) and itch provocations between patients with 
rheumatoid arthritis and psoriasis. The patients with 
psoriasis had an increased itch response to histamine 
iontophoresis (visual analogue scale (VAS)=3, 0–10 
scale), but not electrical itch stimulation, while the 
patients with rheumatoid arthritis displayed decreased 
tolerance to painful stimuli (cold pressor test and me-
chanical stimulation) indicative of pathway-specific 
pruriceptive and nociceptive sensitization, respectively 
(20). At the same time, a few studies using QST indi-
cate that sensory aberrations, particularly associated 
with thermal parameters and conditioned pain modu-
lation, are present in patients with itch, as have also 
been thoroughly established and utilized for a number 
of pain conditions. However, some studies are notably 
in disagreement with the concept of central sensiti-
zation as a significant feature in relation to chronic 
itch (21–24). Finally, several treatment opportunities 
represent commonalities; as with chronic pain, itch oc-
casionally responds to, for example, topical capsaicin, 
anticonvulsants, local anaesthetics, and homotopic 
cold counter-stimulation (3, 14). Interestingly, and in 
complete contrast to the aforementioned, a frequent 
side-effect of μ-opioid analgesics is induction of 
severe itch, which is thought to be, at least in part, a 
consequence of decreased activity in the dorsal horn 
neurons of the nociceptive system, thereby causing 
spinal disinhibition of itch-signalling (25). The para-
doxical itch response to opioids underlines the notion 
of separate neuronal pathways and central proces-
sing of itch and pain. In relation to pain processing, 
non-neuronal glial cells are widely accepted to play 
a significant role in the initiation or maintenance of 
pain. Central glia, foremost astrocytes and microglia, 
have been extensively implicated in pain processing, 
and more recently a number of studies have emerged 
focusing on the role of peripheral glia, e.g. satellite glial 
cells (SGCs) in relation to pain. Recent accumulating 
evidence reviewed here proposes a possible interaction 
between glial cells and pruriceptive neurons that might 
play a role in the chronification of itch.
NEURON-GLIA INTERACTIONS IN PAIN – AND 
ITCH?
A large amount of strong evidence supports a role of 
glial cells in relation to both neuropathic and inflam-
matory pain (26–28). The neuron-glia interactions are 
shown to be crucial in modulating several induced 
pathological pain conditions particularly associated 
with sub-acute and chronic pain (29, 30). Neuronal 
excitability of nociceptive circuits can be extensively 
augmented by neurotransmitters, but also by immune 
mediators directly released from, or modulated by, 
glial cells, such as microglia, astrocytes and, to a 
lesser extent, oligodendrocytes (28). The notion of 
neuro-inflammation as a maintainer of pain-induced 
hyperexcitability and pain chronification has promp-
ted similar research related to the role of glial cells in 
prolongation or chronification of itch (11, 12). New 
strategies considered promising in glial modulation of 
some pathological pain states, which could be equally 
applicable and important for itch modulation and treat-
ment. Table I highlights recent and important findings 
on the contribution of glial cells in itch processing.
Drawing on these parallels between itch and pain 
opens up the possibility of understanding the underlying 
mechanisms of chronification and potential modula-
tion of itch (26, 29). Considering the fact that itch and 
pain are mediated mostly by primary afferent C-fibres 
with their cell bodies located in the dorsal root ganglia 
(DRG) or the trigeminal ganglia (TG), the interactions 
between neuronal tissue conveying itch and the non-
neuronal component (e.g. SGCs) at the level of the 
sensory ganglia, are hypothesized to be similar to the 
established interactions between SGCs and nociceptive 
Table I. Summation of the current knowledge on glial cells contribution to modulation of itch
Glial cell type Itch model/condition Mechanism(s) Ref.
Central glial cells
Astrocytes Topical DCP (contact dermatitis) and 
NC/Nga mouse strain (atopic dermatitis)
Itch and repeated scratching shown to induce STAT3 enhancing central itch 
transmission via LCN2-signalling with GRPR+ neurons
(11, 46, 
47)
Microglia Topical DNFB (model of contact 
dermatitis)
Microglia-maintained pruritus induced by DNFB via activity in the FKN/CX3CR1/
p38MAPK. The itch was reversible by minocycline, a microglial inhibitor
(12, 13)
Oligo-dendrocytes N/A for itch (shown to modulate pain) N/A for itch (shown to modulate pain) (68, 69)
Peripheral glial cells
Satellite glial cells N/A for itch (shown to modulate pain) N/A for itch (shown to modulate pain) (52, 53)
Schwann cells HES-related pruritus and prurigo 
nodularis
HES-infusing therapy frequently causes persistent itch, which is probably 
a consequence of long-term HES-storage in Schwann cells. Schwann-cell 
morphological alterations have been observed in prurigo nodularis.
(49–51)
DCP: diphenylcyclopropenone; DNFB: 2,4-dinitrofluorobenzene; GRPR+: gastrin-releasing peptide receptor (positive); HES: hydroxyethyl starch; LCN2: 
lipocalin-2; N/A: not applicable; STAT3: signal transducer and activator of transcription 3.
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afferents (31, 32). If peripheral glial cells are capable of 
inducing or maintaining hyperexcitability in the sensory 
neurons under inflammatory or neuropathic pain con-
ditions, a possible explanation of pain chronification, 
similar processes would probably occur in relation to 
itch chronification (which is also frequently associated 
with neuropathy or inflammation). A recent study has 
highlighted the role of CXCL10/CXCR3 signalling 
within the DRG after the development of squaric acid 
dibutylester (SADBE)-induced allergic contact derma-
titis (ACD) as a model of skin inflammation and itch 
(33). The study did not exclude a glial or leukocyte 
origin of the CXCL10/CXCR3-overexpression, and 
since the receptor is established to be intricately involved 
in aberrant glial signalling during painful states (34), 
non-neuronal cells were probably contributing to the 
mediation of allergic itch. The following section aims 
at comparatively describing the current knowledge on 
the role of central and peripheral glial cells in relation 
to itch, while drawing parallels with available and 
more abundant knowledge established in relation to the 
contribution of activated glial cells in pain processing. 
Microglia and itch
Microglia are central nervous system (CNS)-residing 
macrophages of erythro-myeloid origin (35) known 
to carry out immune-regulatory tasks within the CNS. 
Spinal microglia are well known to be activated in 
chronic pain and neuroinflammatory models, a pro-
cess known as “microgliosis” (36, 37). Activation of 
microglia leads to the release of inflammatory substan-
ces, including interleukin (IL)-1b, IL-6, and tumour 
necrosis factor (TNF) α, which are known to contribute 
to pain maintenance and chronification (38). To test 
whether scratching activated spinal microglia, Zhang 
et al. (13) deployed an itch model by application of 
5’-guanidinonaltrindole (GNTI; a κ-opioid antagonist) 
and compound 48/80 in mice to induce itch and subse-
quent scratching. The group demonstrated that spinal 
microglia were highly activated by prolonged itch and 
scratching, reflected in an elevated expression of p-p38, 
and the microglial activation marker CD11b (12, 13). 
However, since scratching is usually associated with 
pain and tissue-damage it remains to be elucidated to 
what extent scratching per se provokes microgliosis. 
Nalfurafine, a κ-opioid receptor agonist, reversed these 
expressions and reduced the scratching. While μ-opioid 
receptor agonists frequently cause severe itch, κ-opioid 
receptor agonists are notably shown to have an anti-
pruritic effect (25, 39). Elaborating on these results, 
a recent study induced chronic contact dermatitis-like 
pruritus in mice by repeated topical administration of 
2,4-dinitrofluorobenzene (DNFB) and showed that 
scratching was associated with activation of spinal 
microglia via the p38 MAPK path way (12, 13). In 
addition, the group used intrathecally delivered p38 
inhibitor and minocycline (a microglial inhibitor) to 
significantly reduce severe scratching in the DNFB-
treated mice. They also applied antiserum against both 
CX3CR1 and fractalkine (FKN) to examine the effect 
on scratching and highlighted a role of fractalkine/
CX3CR1 signalling in the development of pruritus. 
The FKN/CX3CR1/p38MAPK pathways are also 
well-established to be involved in the development of 
neuropathic pain (40). Interestingly, minocycline ad-
ministration has also occasionally been associated with 
an antipruritic effect in humans, particularly in patients 
with prurigo pigmentosa. However, the mechanism 
behind this effect is unclear and could be unrelated to 
the glial modulatory function of minocycline (41, 42). 
Astrocytes and itch
Astrocytes also play a critical role in chronic pain 
(26–28). Astrocyte activation, known as “astrogliosis”, 
includes up-regulation of the astrocytic markers, most 
prominently glial fibrillary acidic protein (GFAP) and 
is generally a longer lasting phenomenon than micro-
gliosis (43–45). 
In one study, mice with chronic atopic itch underwent 
resiniferatoxin-induced TRPV1-ablation, resulting in a 
decreased expression of GFAP and reduced scratching 
behaviour, showing that a link may exist between pru-
ritus, cutaneous pain caused by scratching and central 
astrocytic dysregulation (11, 46). Furthermore, Shira-
tori-Hayashi et al. (11) demonstrated that the signalling 
pathway involved in itch-induced astrogliosis in chronic 
itch includes increased STAT3-signalling since the ex-
pression of this marker was highly augmented in two 
mice models of itch (AD; NC/Nga mice and contact der-
matitis; diphenylcyclopropenone (DCP)-induced) (11, 
46). Furthermore, the subsequent injection of the JAK-
inhibitor AG490 blocked both the STAT3 expression and 
reversed the scratching behaviour. The protein, LCN2 
secreted from active astrocytes, was found to be highly 
expressed in the spinal cord after the itch induction and 
declared to be a likely mediator of the enhancement of 
spinal itch signalling in the applied surrogate models 
(11, 46). Hence, LCN2 could be a potential pharmaco-
logical target for future treatment of chronic itch. Very 
recently, Liu et al. (47) observed marked astrogliosis 
in male mice in response to an acetone, diethyl ether 
and water-induced (AEW) model of chronic xerotic 
pruritus and alloknesis. The study showed a distinct role 
of Toll-like receptor 4 (TLR4)-signalling in astrocytic 
activation upon pruritic stimulation and notably obser-
ved that intrathecal injection of the astroglial inhibitor 
L-α-aminoadipate reduced AEW-induced chronic itch 
and associated alloknesis without affecting responses to 
acute models of itch induced by compound 48/80 and 
chloroquine. Lastly, it was shown that scratching in re-
sponse to AEW application was essential to the induction 
of spinal astrogliosis, since it was nearly abolished by 
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the use of Elizabethan collars. Astrogliosis has, until re-
cently, been described primarily as a phenomenon found 
in models of chronic pain following a nerve injury (48). 
Peripheral glial cells and itch
Glial cells in the periphery include Schwann cells 
ensheathing peripheral nerve fibres and providing 
myelination to certain fibre types and SGCs surroun-
ding the neuronal somata in the DRG and sharing 
several functional commonalities with the astrocytes. 
Coincidentally, Schwann cell dysfunction has been 
implicated in prolonged itch. After hydroxyethyl starch 
(HES)-infusion therapy, typically in response to blood 
loss, a common adverse effect is severe protracted itch. 
Exploratory studies indicate that this is a consequence 
of HES-accumulation in myelinating and unmyelina-
ting Schwann cells inducing functional disturbances 
(49, 50). This phenomenon has also been described in 
prurigo nodularis, a chronic dermatological itch condi-
tion, but the specific molecular mechanism(s) remains 
to be elucidated (51). Our group has focused on glial 
cells in the periphery and has shown that glial cells of 
TG are intricately involved in trigeminal pain proces-
sing (52, 53) and that SGCs of the DRG are potential 
contributors in cisplatin-induced neuropathic pain (54), 
a sensory condition also frequently associated with itch 
(55). Several groups have also shown the activation and 
involvement of peripheral glia in different models of 
inflammatory or neuropathic pain (26, 31). Therefore, 
there might also be a potential contribution of peripheral 
glia including SGCs and Schwann cells in the patho-
genesis of chronic itch. See Fig. 1 for an illustration of 
potential mechanisms, in which central and peripheral 
glial cells are shown or hypothesized to modulate itch.
Interventional opportunities for modulation of neuro-
glial interactions
Besides neuron-glial cross-talk, mast cell–glia com-
munication has also been proposed as a mechanism 
contributing to neuro-inflammation, both at the level of 
the peripheral system and in the CNS (56). Palmitoyl-
ethanolamide (PEA), a fatty acid amide known to 
regulate neurogenic pain, inflammation, and pruritus, 
is produced and hydrolysed by microglia and can at-
tenuate activation of mast cells (57–59). Abbramo et 
al. (60) have shown that the endogenous production of 
PEA is elevated in the lesional skin of dogs with AD 
compared with healthy controls, indicating a protective 
role in an experimental model of canine AD.
Another therapeutic opportunity is low-dose naltrexo-
ne (LDN), which has been found to reduce symptoms 
of pain in a number of pathological conditions, such as 
fibromyalgia and complex regional pain syndrome, and 
additionally to significantly reduce itch associated with 
systemic sclerosis in a case series (61, 62). Naltrexone 
has two distinct mechanisms. It is a well-known anta-
gonist of µ-opioid receptors, but also an antagonist of 
the non-opioid receptor TLR4, which is expressed on 
macrophages and microglia. Via this signalling pat-
hway, the LDN yields anti-inflammatory effects. Given 
the wide variety of inflammatory factors produced by 
activated microglia (e.g. pro-inflammatory cytokines, 
substance P, nitric oxide, and excitatory amino acids), 
application of LDN suppresses microglial activation. 
Fig. 1. Recently explored and theoretically hypothesized neuro-glial interactions, which could modulate itch signalling from the periphery to the central 
nervous system. Schwann cell dysfunction could result in increased signalling, either directly by, e.g. induction of ectopic firing, or indirectly by disinhibition 
of stimuli (nociceptive, thermal, and mechanical fibres), which normally inhibit pruritic stimuli at the spinal cord level. Note that, contrary to popular 
belief, C-fibre axons are invaginated in Schwann cells, but not myelinated (70). SGCs of the DRG (marked “?”) could interact with the pruriceptive fibres 
to modulate itch signalling. Similarly, inside the central nervous system, astrocytes and microglial cells have been shown to increase pruritic signalling 
of central afferent pruriceptive neurons through separate molecular mechanisms. SGC: satellite glial cells; DRG: dorsal root ganglia.
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This effect is not limited to the CNS and occurs in the 
periphery, as supported by findings showing diminished 
levels of TNF-α, IL-6, monocyte chemotactic protein 1 
(MCP-1), and other inflammatory agents from periphe-
ral macrophages. It is possible that naltrexone (mainly 
used in human studies) and naloxone (mainly used in 
animal models) act partly via glial cells to exert their 
analgesic, anti-inflammatory, and perhaps anti-pruritic 
effects partly independent of opioid receptors (61–63).
CONCLUSION AND FUTURE DIRECTIONS
Recent research has unveiled a number of non-neuronal 
cells, including glial cells, which are involved in acute 
as well as chronic itch processing. Mechanisms have, 
until now, been described for astrocytes, microglia, and 
indirectly for Schwann cells (13, 46, 49, 50, 64). Whether 
glial cells, such as SGCs and oligodendrocytes, also con-
tribute in modulation of itch and to what extent, remains 
to be explored. Moreover, future research is necessary 
to assess whether pathway-specific histaminergic vs. 
non-histaminergic itch would prompt different patterns 
of glial activation, and thus potentially require different 
targeted interventions. Presently, specific glial modulators 
for human use are lacking. However, a number of com-
pounds with a glial modulatory effect (e.g. fluorocitrate, 
minocycline, ibudilast, and even vitamin D) are availa-
ble. The anti-nociceptive effects of some of these agents 
have been reported in animal models of pain and some 
human studies (27, 65, 66). Attempts so far have been 
quite limited and yielded mixed results. Proof-of-concept 
studies and randomized controlled trials are needed in 
order to evaluate the efficacy of these and other potential 
agents that may prove beneficial in treatment of painful 
and pruritic conditions. For therapeutic glial modulation, 
it should be considered that complete attenuation of glial 
function is not advantageous and is probably associated 
with significant adverse effects, because these cells, e.g. 
astrocytes and microglia, exert vital housekeeping and 
surveillance functions in the nervous system (67). The 
selectivity of future potential candidates needs to be tested 
in proper experimental models, since most preclinical 
studies have focused on early time-points in pain and/or 
itch models, whereas the equivalent clinical problems are 
usually chronic. Glial modulation of itch is a field in its 
very infancy, and significant bench-to-bedside hindrances 
necessitate additional studies before glial modulation 
therapy can be clinically utilized.
The authors declare no conflicts of interest.
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